This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1087057107312778v1 13/2/101    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Szekeres, P. G. Articles by Karran, E. H. Search for Related Content PubMed PubMed Citation Articles by Szekeres, P. G. Articles by Karran, E. H. Social Bookmarking                         What's this?

Development of Homogeneous 384-Well High-Throughput Screening Assays for A1-40 and A1-42 Using AlphaScreen^TM Technology

Eli Lilly & Co. Ltd.

^* To whom correspondence should be addressed. E-mail: szekeresp{at}lilly.com.

	Abstract

Amyloid beta (A) peptides are the major constituent of amyloid plaques, one of the hallmark pathologies of Alzheimer’s disease. Accurate and precise quantitation of these peptides in biological fluids is a critical component of Alzheimer’s disease research. The current most established assay for analysis of A peptides in preclinical research is enzyme-linked immunosorbent assay (ELISA), which, although sensitive and of proven utility, is a multistep, labor-intensive assay that is difficult to automate completely. To overcome these limitations, the authors have developed and optimized simple, sensitive, homogeneous 384-well assays for A1-42 and A1-40 using AlphaScreen^TM technology. The assays are capable of detecting A peptides at concentrations <2 pg/mL and, using a final assay volume of 20 µL, routinely generate Z' values >0.85. The AlphaScreen^TM format has the following key advantages: substantially less hands-on time to run, easier to automate, higher throughput, and less expensive to run than the traditional ELISA. The results presented here show that AlphaScreen^TM technology permits robust, efficient, and cost-effective quantitation of A peptides. (Journal of Biomolecular Screening XXXX:xx-xx)

First published on January 23, 2008, doi:10.1177/1087057107312778

Journal of Biomolecular Screening 2008;13:101.

A more recent version of this article appeared on February 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Harndahl, S. Justesen, K. Lamberth, G. Roder, M. Nielsen, and S. Buus Peptide Binding to HLA Class I Molecules: Homogenous, High-Throughput Screening, and Affinity Assays J Biomol Screen, February 1, 2009; 14(2): 173 - 180. [Abstract] [PDF]